If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
ActRIIB-Fc decoy receptor fusion protein · myostatin pathway
Research documentation
Ask sales for the ACE-031 batch COA and the analytical evidence needed to qualify the material for your study. Confirm the available purity and identity records, lot continuity, handling information, and method requirements before ordering.
Overview
ACE-031 acts as a soluble ligand trap: human Activin Receptor Type IIB (ActRIIB), reduced to its extracellular ligand-binding region, is fused to a human IgG1 Fc, and the resulting fusion sequesters myostatin, activin A, and related TGF-β superfamily ligands before they can engage membrane-bound ActRIIB on muscle and other tissues. Removing myostatin's tonic restraint on skeletal-muscle growth drives increased muscle mass — the rationale behind the molecule's clinical program in Duchenne muscular dystrophy and other wasting conditions, a program halted in Phase 2 owing to off-target effects. Structurally it is a recombinant, glycosylated receptor-Fc chimera rather than a synthetic peptide. Lyochem supplies ACE-031 as a lyophilized reference standard — a recombinant fusion protein — to a ≥95% purity specification (SEC/RP-HPLC). Its glycoprotein nature dictates a biologics-style release panel: RP-HPLC for chemical purity, reducing and non-reducing SDS-PAGE to resolve size and disulfide arrangement, LC-MS/MS peptide mapping for sequence coverage, glycan profiling across the ActRIIB-ECD and Fc portions, and a myostatin-binding bioactivity assay. The 1 mg fill aligns with typical aliquot volumes for receptor-pharmacology work.
Applications & buyer fit
Other research peptides in this category — Melanotan I, Melanotan II, PT-141, ACE-031, Adipotide / FTPP, EPO, HCG, HMG — ship to research labs studying topics outside the GH / cognitive / immune / mitochondrial / repair / longevity / Khavinson clusters. Each peptide has its own analytical-packet emphasis (e.g. glycoprotein bioassay in IU/mg for HCG; cyclised-form confirmation for oxytocin) noted in the per-product CoA scope.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every lot has its own batch-specific CoA — HPLC purity and MS identity, plus any analytical scope agreed at quote stage — tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
A recombinant fusion protein. Per-batch COA data should be used to verify identity, the glycosylation profile, and the expression system. Offered for research use only.
Selected literature
Frequently asked questions
A recombinant ActRIIB-Fc construct is characterized by a panel rather than a single test. SDS-PAGE under reducing and non-reducing conditions reports apparent molecular weight and confirms the disulfide-linked dimer versus monomer, flagging clipping or aggregation. Intact-mass LC-MS establishes the deconvoluted mass including expected glycosylation heterogeneity, while size-exclusion chromatography quantifies monomer content and any high-molecular-weight species. For sequence-level confirmation, tryptic-digest peptide mapping by LC-MS/MS verifies the ActRIIB extracellular-domain and Fc regions. Together these establish that the delivered protein matches the intended fusion design before it enters binding studies.
At the 10-1000 nM range, surface adsorption is the main threat to accurate results, so reconstitute and dilute in cell-culture-grade buffer containing a carrier such as 0.1% BSA to limit loss to vessel walls. Minimize freeze-thaw stress by aliquoting the reconstituted protein for single use and holding aliquots cold, since repeated cycling promotes the aggregation that SEC would later detect. Before a critical binding run, it is prudent to re-confirm monomer integrity, because a decoy-receptor protein that has partially aggregated will report a misleadingly low active concentration against myostatin and related ligands.
Related peptides